Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Invested Capital (2020 - 2025)

Candel Therapeutics' Invested Capital history spans 4 years, with the latest figure at $21.6 million for Q4 2023.

  • On a quarterly basis, Invested Capital fell 68.05% to $21.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $21.6 million, a 68.05% decrease, with the full-year FY2023 number at $21.6 million, down 68.05% from a year prior.
  • Invested Capital hit $21.6 million in Q4 2023 for Candel Therapeutics, down from $29.1 million in the prior quarter.
  • Over the last five years, Invested Capital for CADL hit a ceiling of $83.8 million in Q1 2022 and a floor of -$42.7 million in Q2 2021.
  • Historically, Invested Capital has averaged $29.2 million across 4 years, with a median of $34.4 million in 2023.
  • The widest YoY moves for Invested Capital: up 528.78% in 2021, down 245.63% in 2021.
  • Tracing CADL's Invested Capital over 4 years: stood at -$23.1 million in 2020, then surged by 380.33% to $64.7 million in 2021, then rose by 4.66% to $67.7 million in 2022, then tumbled by 68.05% to $21.6 million in 2023.
  • Business Quant data shows Invested Capital for CADL at $21.6 million in Q4 2023, $29.1 million in Q3 2023, and $34.4 million in Q2 2023.